Search

Arcus Biosciences Inc

Chiusa

SettoreSettore sanitario

24.06 -2.08

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

23.98

Massimo

24.93

Metriche Chiave

By Trading Economics

Entrata

37M

-91M

Vendite

24M

41M

EPS

-0.72

Margine di Profitto

-221.951

Dipendenti

601

EBITDA

38M

-85M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+56.97% upside

Dividendi

By Acuity

Utili prossimi

26 ott 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

257M

3.7B

Apertura precedente

26.14

Chiusura precedente

24.06

Arcus Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 set 2026, 20:21 UTC

Arcus Biosciences Inc shares are lower in after-market hours, marking seven consecutive sessions of declines. No specific news was identified for the price movement.

11 set 2026, 21:21 UTC

Arcus Biosciences Inc shares are lower in after-market trading, continuing a recent trend. No specific company news was identified to explain the decline.

10 set 2026, 20:01 UTC

Arcus Biosciences Inc shares are sharply lower today, breaking a recent trend of higher closes. Unusually high trading volume may be influencing the decline.

9 set 2026, 20:07 UTC

News

Shares of Arcus Biosciences are lower today, despite anticipation of a significant data update in October following a recent presentation at Citigroup's summit.

8 set 2026, 20:07 UTC

Arcus Biosciences Inc shares are lower today, continuing a decline since Friday's close. The stock is trading near the lower end of its one-month range.

2 set 2026, 20:08 UTC

Correlated Moves

Arcus Biosciences Inc. shares are higher today, supported by gains in the biotechnology sector and trends in related ETFs. The stock has stabilized after fluctuations.

28 ago 2026, 20:02 UTC

Arcus Biosciences shares are lower today, breaking a trend of higher closes. Rising U.S. Treasury yields may be impacting investor sentiment in biotechnology.

26 ago 2026, 20:08 UTC

Arcus Biosciences Inc shares are lower during Wednesday's session amid mixed market performance and inflation data, with no specific company news identified for the decline.

20 ago 2026, 19:36 UTC

Correlated Moves

Arcus Biosciences shares are lower, reflecting a broader decline in the biotechnology sector amid first-quarter results indicating a notable drop in price.

19 ago 2026, 19:46 UTC

Correlated Moves

Arcus Biosciences Inc is trading higher, supported by a positive trend in the biotechnology sector. The stock remains above its 20-day moving average.

18 ago 2026, 20:06 UTC

Arcus Biosciences Inc. shares are trading roughly flat amid no specific news. The stock remains above its 20-day moving average.

17 ago 2026, 19:16 UTC

News

Arcus Biosciences Inc is rising as biotechnology sector momentum continues. The company reported second-quarter revenue of $41 million and a net loss of $91 million.

14 ago 2026, 19:46 UTC

Arcus Biosciences Inc is higher today, continuing a positive trend since Thursday's close. The stock remains above its 20-day moving average.

11 ago 2026, 19:56 UTC

News

HC Wainwright raised Arcus Biosciences' Q3 2026 EPS estimate to -$1.00 and maintained a "Buy" rating with a price target of $45.00.

10 ago 2026, 21:02 UTC

Arcus Biosciences Inc shares are higher in after-market trading, continuing a strong upward trend since Monday's close, well above the 20-day moving average.

7 ago 2026, 19:36 UTC

Arcus Biosciences Inc. shares are higher today, trading within a typical range amid investor uncertainty over future monetary policy following a weak jobs report.

6 ago 2026, 20:03 UTC

News

Arcus Biosciences shares are higher as Wells Fargo raises its price target to $23.00 and Wedbush increases its target to $43. Trading volume is notably high.

5 ago 2026, 20:21 UTC

News

Arcus Biosciences reported a net loss of $91 million but exceeded revenue expectations with $41 million. Shares are higher in after-market trading.

4 ago 2026, 21:02 UTC

Arcus Biosciences Inc shares are higher in after-market trading, reflecting positive market sentiment amid easing inflation concerns from U.S.-Iran negotiations.

3 ago 2026, 19:36 UTC

Arcus Biosciences shares are lower today, reflecting broader market dynamics and geopolitical developments impacting investor sentiment. Earlier, shares peaked before declining.

31 lug 2026, 23:16 UTC

Arcus Biosciences Inc. shares are lower in after-market hours, continuing a trend of declining prices and remaining below the 20-day moving average.

30 lug 2026, 18:03 UTC

Arcus Biosciences Inc gains today, supported by a broader market uptick despite geopolitical tensions and inflation concerns. Shares pulled back from earlier session highs.

29 lug 2026, 19:56 UTC

Macro Event

Arcus Biosciences shares are lower amid broader market pressures from steady interest rates and rising crude oil prices, marking five consecutive sessions of decline.

28 lug 2026, 20:06 UTC

Arcus Biosciences Inc shares are lower today, reflecting broader market trends and declines in Asian markets, including significant losses in the Nikkei 225 Index.

27 lug 2026, 21:01 UTC

Arcus Biosciences Inc shares declined in after-market hours, continuing a downward trend over the last four sessions. No specific news was identified to explain the move.

24 lug 2026, 19:06 UTC

News

Arcus Biosciences has signed a clinical supply agreement with AVEO to evaluate casdatifan with tivozanib. Shares are trading lower, reflecting unusual weakness.

22 lug 2026, 20:13 UTC

Arcus Biosciences shares are higher in after-market hours. Broader market volatility is influenced by rising crude oil prices and geopolitical tensions.

21 lug 2026, 19:36 UTC

Arcus Biosciences shares are higher today, supported by overall market strength and positive sentiment in the biotechnology sector. The stock has advanced notably since Monday.

20 lug 2026, 18:06 UTC

News

H.C. Wainwright raised Arcus Biosciences' price target to $45 from $32, maintaining a Buy rating. Shares are higher today following the analyst's upgrade.

Confronto tra pari

Modifica del prezzo

Arcus Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

56.97% in crescita

Previsioni per 12 mesi

Media 38.6 USD  56.97%

Alto 47 USD

Basso 23 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Arcus Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

10 ratings

7

Acquista

3

Mantieni

0

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
help-icon Live chat